Small cell lung cancer (SCLC) is a highly malignant tumor with a very poor prognosis; therefore, more effective treatments are urgently needed for patients afflicted with the disease. In recent years, emerging molecular classifications based on key transcription factors of SCLC have provided more information on the tumor pathophysiology, metastasis, immune microenvironment, and acquired therapeutic resistance and reflected the intertumoral heterogeneity of the various SCLC phenotypes. Additionally, advances in genomics and single-cell sequencing analysis have further revealed the high intratumoral heterogeneity and plasticity of the disease. Herein, we review and summarize these recent lines of evidence and discuss the possible pathogenesis of SCLC.

Epidermal growth factor receptor ( EGFR ) mutations are common oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine kinase inhibitors (TKIs) is beneficial for patients with advanced and early-stage NSCLC. With the development of next-generation sequencing technology, numerous patients have been found to have more than one genetic mutation in addition to a single EGFR mutation; however, the efficacy of conventional EGFR-TKIs and the optimal treatments for such patients remain largely unknown. Thus, we review the incidence, prognosis, and current treatment regimens of EGFR compound mutations and EGFR concomitant mutations to provide treatment recommendations and guidance for patients with these mutations.
Humans ; Carcinoma, Non-Small-Cell Lung/genetics* ; Lung Neoplasms/genetics* ; Protein Kinase Inhibitors/pharmacology* ; Mutation/genetics* ; ErbB Receptors

Objective:To investigate the filial piety value level and the influencing factors of filial piety among children whose parents were diagnosed as advanced cancer.Methods:A convenient sampling method was used to recruit 383 participants in Tumor Hospital, Tianjin Medical University.Results:The total score of Filial Piety Value Scale among children whose parents were advanced cancer patients was (66.50±4.10) . The age of the patient, the number of hospitalization and the degree of awareness of the condition, the age of the children, whether the child was the-only-child, whether the child was living with the patient, and the average daily care time influenced the filial piety values of children whose parents were advanced cancer patients ( Z=16.64-62.94, U=2.04-4.27, P<0.05). Conclusion:Children whose parents were with advanced cancer have a better understanding of filial piety. Nurses understand the values of filial piety of children in the context of traditional filial piety and family care mode in China, which can enhance the experience of filial piety and filial piety of both children and parents, also improve the mental health problems of patients, and finally improve the quality of life of patients with advanced cancer.

Immune checkpoint inhibitor (ICI) has become one of the important therapeutic strategies for the patients with advanced non-small cell lung cancer (NSCLC). The latest clinical studies have shown that immunotherapy can bring more survival benefits to patients with early lung cancer and operable patients with locally advanced lung cancer. However, the strategies of neoadjuvant immunotherapy, the timing of operation, the evaluation system of curative effect, predictive markers and other problems still need to be explored in the clinical practice of large samples. This paper reviews the progress of neoadjuvant immunotherapy in NSCLC.

Precision detection techniques have promoted the development of individualized diagnosis and treatment of tumors in the era of precision medicine. At the same time, clinical demands of precision treatments have further driven the development and application of precision detection techniques. In recent years, precision medical detection techniques realized rapid transformations from low-throughput to high-throughput genomic sequencing, from tissue biopsies to liquid biopsies, and from multicell promiscuous detection to single cell precision sequencing. All these changes have promoted the emergence and development of new technologies, new targets, and new drugs in the era of precision oncology medicine. In the future, multi-dimensional combined detection could help to improve the accuracy of precision medicine; ctDNA methylation detection analysis could broaden the research field of precision medicine; and the transformation of clinical trial design could also contribute to promote the in-depth development of precision medicine.

[Abstract] In recent years, investigation on immune checkpoint inhibitors has made exciting progress in anti-tumor therapy. Through continuous exploration, there is a deeper understanding of intermolecular interaction patterns among PD-L1, PD-1, CD80, CTLA-4, etc. In addition to classically acting as a T cell inhibitory receptor, PD-L1 was found to be co-expressed with PD-1 or CD80 on the same cell and play a positive immunoregulatory function through cis-interaction, significantly affecting the interaction network between tumor cells and immune cells and the efficacy of immunotherapy, and bringing new changes to the understanding of the mechanisms of cancer immunotherapy. This review provides an in-depth analysis of the cis-PD-L1/PD-1 and cis-PD-L1/CD80 pathways and their interactions with a complex network of CTLA-4 and CD28 molecules, finally outlines the effects of blocking this cis-interaction pathway on T cell signaling, cytotoxic function, and the efficacy of anti-tumor immunotherapy.

Objective:To test the reliability and validity of the Chinese version of the Quality of Life in Adult Cancer Survivors (QLACS) in Chinese cancer Survivors.Methods:We translated the scale following the procedure of translation, integration and back translation. After modifying the scale and adapting it in Chinese culture, the reliability and validity of the QLACS scale was tested in a large sample of 222 cancer survivors.Results:The Chinese version of QLACS had 47 items with a total of twelve domains. Principal component analysis resulted in an 8-factor structure of the explaining 74.393% of the seven generic domains′ variance, and an 5-factor structure of the explaining 71.937% of the five cancer-specific domains′ variance. The item level content validity index (I-CVI) was 0.89-1.00, and the total content average content validity index (S-CVI/) was 0.93. The Cronbach′s α coefficient for the total QLACS score was 0.935, and 0.933 for generic domains, and 0.865 for cancer-specific domains.Conclusions:The Chinese version of QLACS appears to possess adequate validity, reliability and internal consistency. The newly translated Chinese version of QLACS may be used to assess the quality of cancer survivors in China.

Objective:To develop an assessment instrument for evaluating Filial Piety Value Scale among Children Whose Parents were Advanced Cancer Patients and to test the reliability and validity of the tool.Methods:Through literature review, semi-structured interview and expert letter consultation, the first version of the Filial Piety Value Scale (FVS) was developed. A convenience sampling method was adopted to recruit 352 children of patients with advanced cancer as respondents. Item analysis, reliability and validity were adopted to evaluate the items, and finally the formal version of FVS was developed.Results:The Internal Consistency of FVS was 0.86, and the content validity index of each item was 0.93-1.00.Two factors were extracted from exploratory factor analysis, and the cumulative contribution rate of variance was 60.25%. The two factors were named as Care (10 items) and Respect (5 items).The correlation coefficient between the total score of FVS and the total score of Filial Piety Values Index (FVI) was 0.496, and the correlation coefficient between the FVS total score and FVI Care and Respect score was 0.50 and 0.46, and the results were statistically significant ( P<0.01). Conclusion:The Filial Piety Value Scale of children whose parents were advanced cancer patients has good reliability and validity, which can be used to evaluate the filial piety value of children whose parents are advanced cancer.

Immune checkpoint inhibitors (ICIs) therapy is the most commonly used immunotherapy regimen at present. It has been approved for clinical treatment of melanoma, kidney cancer, head and neck cancer, bladder cancer and other tumors. It has made a breakthrough in the treatment of lung cancer and become a new pillar of comprehensive treatment of lung cancer. However, ICIs alone is less effective in non-selective patients, and combination therapy has become a hot topic of exploration. This article focuses on the development of combined immune checkpoint inhibitors and describes how immunotherapy can be used to treat early stage cancer.

When cancer patients lose their independence and turn to depend on others after illness, their sense of personal value and meaning of life gradually lose, psychological pain increase, depression and anxiety occur, and their will to survive is lost because of despair and sense of burden towards other people. This paper introduces a new type of psychotherapy aiming at improving the sense of life value of cancer survivors, i.e. meaning-centered group psychotherapy. It summarizes the related concepts and theoretical sources, implementation methods and applications, and enlightenment of the application of this therapy in cancer survivors in China, with a view to providing clinical nurses with new nursing methods for cancer survivors.